4.8 Article

Elevated Lipogenesis and Diminished Cholesterol Synthesis in Patients With Hepatitis C Viral Infection Compared to Healthy Humans

期刊

HEPATOLOGY
卷 57, 期 5, 页码 1697-1704

出版社

WILEY
DOI: 10.1002/hep.25990

关键词

-

资金

  1. Canadian Institutes of Health Research
  2. Natural Sciences and Engineering Research Council of Canada

向作者/读者索取更多资源

Hepatitis C virus (HCV) exerts a profound influence on host lipid metabolism. It has been suggested that the synthesis of both fatty acids (FA) and cholesterol is dysregulated in HCV but this has not been directly quantified in humans. The purpose of this study was to measure lipogenesis and cholesterol synthesis using stable isotopes in patients with HCV (n = 5) and healthy control (n = 9) subjects recruited from the University of Alberta hospital. Blood samples were taken at fasting (0 and 24 hours) and after meals over the day to mimic typical food consumption and postprandial metabolism. Isolation of free cholesterol (FC), cholesteryl ester (CE), and triglyceride (TG) from plasma and very low-density lipoproteins (VLDL) was used to measure FA and cholesterol synthesis using deuterium uptake and isotope ratio mass spectrometry. FA composition was analyzed by gas chromatography. VLDL-TG levels of polyunsaturated fatty acids (PUFA), including linoleic and linolenic acid, were lower in HCV compared to control (P < 0.05 for both). Fasting hepatic lipogenesis was significantly higher in HCV (2.80 +/- 0.55%) compared to control (1.19 +/- 0.27%; P = 0.03). Conversely, fasting whole-body synthesis of FC (HCV 1.64 +/- 0.28% versus control 8.78 +/- 1.59%) and CE (HCV 0.26 +/- 0.08% versus control 1.92 +/- 0.25%), as well as hepatic FC synthesis (HCV 1.68 +/- 0.26% versus control 8.12 +/- 0.77%) was lower in HCV (P < 0.001 for all). Conclusion: These data provide evidence that lipogenesis is elevated while cholesterol synthesis is impaired in HCV, supporting previous findings from cellular and animal models. Low PUFA levels combined with elevated lipogenesis suggests a role for dietary PUFA supplementation in HCV patients. (HEPATOLOGY 2013;57:1697-1704)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据